Comment from Baravik Mark

Peptide therapy represents an evolving area of medicine that deserves thoughtful consideration rather than dismissal. Peptides are naturally occurring amino acid chains that play critical roles in physiological signaling, and therapeutic use is grounded in this biological foundation. When developed and used responsibly, peptide-based treatments have demonstrated potential in areas such as metabolic regulation, tissue repair, hormone balance, and immune modulation. Critics often raise concerns about regulation and variability in product quality, which are valid points. However, these concerns should drive stronger oversight and standardization—not wholesale rejection of the therapy itself. Many widely accepted treatments in modern medicine began as emerging or controversial approaches before sufficient research, regulation, and clinical experience established their role. There is a growing body of clinical and preclinical evidence supporting certain peptides, and ongoing research continues to clarify their safety profiles, mechanisms, and appropriate indications. As with any therapy, patient selection, dosing, and monitoring are critical, and care should always be guided by trained medical professionals using evidence-based practices. Dismissing peptide therapy outright risks overlooking meaningful therapeutic opportunities. A more balanced approach—supporting rigorous research, ensuring product quality, and promoting responsible clinical use—will better serve patients and the advancement of medicine.